Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
KraneShares MSCI All China Health Care Index ETF (KURE) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KraneShares MSCI All China Health Care Index ETF (KURE) - free report >>
Image: Bigstock
China Healthcare ETF (KURE) Hits New 52-Week High
Investors seeking momentum may have KraneShares MSCI All China Health Care Index ETF (KURE - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of KURE are up approximately 53.9% from their 52-week low of $18.79/share.
But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.
KURE in Focus
KURE looks to track the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. KURE charges investors 65 basis points in fee per year.
Why the move?
Chinese biotech and pharma companies are benefiting from the push for coronavirus vaccine. The private Chinese company Sinovac Biotech is testing an inactivated vaccine called CoronaVac. On June 13, the company announced that “Phase I/II trials on 743 volunteers found no severe adverse effects and produced an immune response.”
More Gains Ahead?
The fund has a weighted alpha of 47.52, per barchart.com. So, there is a decent outlook ahead for those who want to ride this surging ETF a shade further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>